Literature DB >> 12601448

[Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out].

W Koch1, P Knesewitsch, K Tatsch, K Hahn.   

Abstract

In radioiodine therapy for malignant thyroid disease, the pre-therapeutically administered iodine-131-dose can reduce the potential of thyroid or thyroid carcinoma cells to absorb the following therapeutic iodine-131-dose, possibly leading to its failure. This so called stunning effect is controversially discussed in the scientific community. Here we summarize and evaluate publications with regard to the existence and the effects of stunning as well as possible countermeasures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601448

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  2 in total

1.  Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

Authors:  C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald
Journal:  Endocrine       Date:  2020-03-16       Impact factor: 3.633

2.  Lesion-Wise Comparison of Pre-Therapy and Post-Therapy Effective Half-Life of Iodine-131 in Pediatric and Young Adult Patients with Differentiated Thyroid Cancer Undergoing Radioiodine Therapy.

Authors:  Praveen Kumar; Chandrasekhar Bal; Nishikant Avinash Damle; Sanjana Ballal; S N Dwivedi; Sandeep Agarwala
Journal:  Nucl Med Mol Imaging       Date:  2019-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.